Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer

Bonnie Hylander, Elizabeth Repasky, Protul Shrikant, Marilyn Intengan, Amy Beck, Deborah Driscoll, Pankaj Singhal, Shashikant Lele, Kunle Odunsi

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objectives. The identification of proteins that are selectively expressed in cancer and with potential to elicit an immune response is the first step towards antigen-specific immunotherapy. The Wilms tumor gene product (WT1) is inherently immunogenic and is now thought to be oncogenic. The aim of this study was to determine the expression of WT1 in epithelial ovarian cancer (EOC) and correlate with clinico-pathologic characteristics. Methods. WT1 expression was examined using immunohistochemistry applied on a tissue microarray of normal tissues and a panel of 100 EOC tissues. The distribution of WT1 expression and clinico-pathologic variables were analyzed. Survival probabilities were estimated by Kaplan-Meier method, and statistical significance was determined by the log-rank test. Results. WT1 expression was observed in 78/100 of specimens. The predominant expression pattern was homogenous, occurring in 66/100 (66%) of WT1-positive specimens, while 12/100 (12%) demonstrated heterogeneous staining. In normal tissues, WT1 expression was noted in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary. The median follow-up of the patient population was 30 months. Patients with WT1-positive tumors tended to have a higher grade (P = 0.006) and stage (P = 0.002) of tumor. However, there were no significant differences in the distribution of patients with WT1-positive tumors in relation to disease-free and overall survival. Conclusions. Our data demonstrate that WT1 is expressed at high frequency in patients with EOC. Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalGynecologic Oncology
Volume101
Issue number1
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Wilms' Tumor Genes
Immunotherapy
Neoplasms
Antigens
Sertoli Cells
Granulosa Cells
Disease-Free Survival
Capsules
Testis
Ovary
Immunohistochemistry
Ovarian epithelial cancer
Staining and Labeling
Kidney
Survival
Population
Proteins

Keywords

  • Immunogenicity
  • Immunotherapy
  • Ovarian cancer
  • Prognosis
  • WT1

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hylander, B., Repasky, E., Shrikant, P., Intengan, M., Beck, A., Driscoll, D., ... Odunsi, K. (2006). Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecologic Oncology, 101(1), 12-17. https://doi.org/10.1016/j.ygyno.2005.09.052

Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. / Hylander, Bonnie; Repasky, Elizabeth; Shrikant, Protul; Intengan, Marilyn; Beck, Amy; Driscoll, Deborah; Singhal, Pankaj; Lele, Shashikant; Odunsi, Kunle.

In: Gynecologic Oncology, Vol. 101, No. 1, 04.2006, p. 12-17.

Research output: Contribution to journalArticle

Hylander, B, Repasky, E, Shrikant, P, Intengan, M, Beck, A, Driscoll, D, Singhal, P, Lele, S & Odunsi, K 2006, 'Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer', Gynecologic Oncology, vol. 101, no. 1, pp. 12-17. https://doi.org/10.1016/j.ygyno.2005.09.052
Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecologic Oncology. 2006 Apr;101(1):12-17. https://doi.org/10.1016/j.ygyno.2005.09.052
Hylander, Bonnie ; Repasky, Elizabeth ; Shrikant, Protul ; Intengan, Marilyn ; Beck, Amy ; Driscoll, Deborah ; Singhal, Pankaj ; Lele, Shashikant ; Odunsi, Kunle. / Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. In: Gynecologic Oncology. 2006 ; Vol. 101, No. 1. pp. 12-17.
@article{3f3b971df2884005bc88ade04439fc9a,
title = "Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer",
abstract = "Objectives. The identification of proteins that are selectively expressed in cancer and with potential to elicit an immune response is the first step towards antigen-specific immunotherapy. The Wilms tumor gene product (WT1) is inherently immunogenic and is now thought to be oncogenic. The aim of this study was to determine the expression of WT1 in epithelial ovarian cancer (EOC) and correlate with clinico-pathologic characteristics. Methods. WT1 expression was examined using immunohistochemistry applied on a tissue microarray of normal tissues and a panel of 100 EOC tissues. The distribution of WT1 expression and clinico-pathologic variables were analyzed. Survival probabilities were estimated by Kaplan-Meier method, and statistical significance was determined by the log-rank test. Results. WT1 expression was observed in 78/100 of specimens. The predominant expression pattern was homogenous, occurring in 66/100 (66{\%}) of WT1-positive specimens, while 12/100 (12{\%}) demonstrated heterogeneous staining. In normal tissues, WT1 expression was noted in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary. The median follow-up of the patient population was 30 months. Patients with WT1-positive tumors tended to have a higher grade (P = 0.006) and stage (P = 0.002) of tumor. However, there were no significant differences in the distribution of patients with WT1-positive tumors in relation to disease-free and overall survival. Conclusions. Our data demonstrate that WT1 is expressed at high frequency in patients with EOC. Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC.",
keywords = "Immunogenicity, Immunotherapy, Ovarian cancer, Prognosis, WT1",
author = "Bonnie Hylander and Elizabeth Repasky and Protul Shrikant and Marilyn Intengan and Amy Beck and Deborah Driscoll and Pankaj Singhal and Shashikant Lele and Kunle Odunsi",
year = "2006",
month = "4",
doi = "10.1016/j.ygyno.2005.09.052",
language = "English (US)",
volume = "101",
pages = "12--17",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer

AU - Hylander, Bonnie

AU - Repasky, Elizabeth

AU - Shrikant, Protul

AU - Intengan, Marilyn

AU - Beck, Amy

AU - Driscoll, Deborah

AU - Singhal, Pankaj

AU - Lele, Shashikant

AU - Odunsi, Kunle

PY - 2006/4

Y1 - 2006/4

N2 - Objectives. The identification of proteins that are selectively expressed in cancer and with potential to elicit an immune response is the first step towards antigen-specific immunotherapy. The Wilms tumor gene product (WT1) is inherently immunogenic and is now thought to be oncogenic. The aim of this study was to determine the expression of WT1 in epithelial ovarian cancer (EOC) and correlate with clinico-pathologic characteristics. Methods. WT1 expression was examined using immunohistochemistry applied on a tissue microarray of normal tissues and a panel of 100 EOC tissues. The distribution of WT1 expression and clinico-pathologic variables were analyzed. Survival probabilities were estimated by Kaplan-Meier method, and statistical significance was determined by the log-rank test. Results. WT1 expression was observed in 78/100 of specimens. The predominant expression pattern was homogenous, occurring in 66/100 (66%) of WT1-positive specimens, while 12/100 (12%) demonstrated heterogeneous staining. In normal tissues, WT1 expression was noted in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary. The median follow-up of the patient population was 30 months. Patients with WT1-positive tumors tended to have a higher grade (P = 0.006) and stage (P = 0.002) of tumor. However, there were no significant differences in the distribution of patients with WT1-positive tumors in relation to disease-free and overall survival. Conclusions. Our data demonstrate that WT1 is expressed at high frequency in patients with EOC. Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC.

AB - Objectives. The identification of proteins that are selectively expressed in cancer and with potential to elicit an immune response is the first step towards antigen-specific immunotherapy. The Wilms tumor gene product (WT1) is inherently immunogenic and is now thought to be oncogenic. The aim of this study was to determine the expression of WT1 in epithelial ovarian cancer (EOC) and correlate with clinico-pathologic characteristics. Methods. WT1 expression was examined using immunohistochemistry applied on a tissue microarray of normal tissues and a panel of 100 EOC tissues. The distribution of WT1 expression and clinico-pathologic variables were analyzed. Survival probabilities were estimated by Kaplan-Meier method, and statistical significance was determined by the log-rank test. Results. WT1 expression was observed in 78/100 of specimens. The predominant expression pattern was homogenous, occurring in 66/100 (66%) of WT1-positive specimens, while 12/100 (12%) demonstrated heterogeneous staining. In normal tissues, WT1 expression was noted in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary. The median follow-up of the patient population was 30 months. Patients with WT1-positive tumors tended to have a higher grade (P = 0.006) and stage (P = 0.002) of tumor. However, there were no significant differences in the distribution of patients with WT1-positive tumors in relation to disease-free and overall survival. Conclusions. Our data demonstrate that WT1 is expressed at high frequency in patients with EOC. Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC.

KW - Immunogenicity

KW - Immunotherapy

KW - Ovarian cancer

KW - Prognosis

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=33644520931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644520931&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.09.052

DO - 10.1016/j.ygyno.2005.09.052

M3 - Article

C2 - 16263157

AN - SCOPUS:33644520931

VL - 101

SP - 12

EP - 17

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -